SG Americas Securities LLC Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

SG Americas Securities LLC grew its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 87.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,242 shares of the company’s stock after buying an additional 3,379 shares during the period. SG Americas Securities LLC’s holdings in Tarsus Pharmaceuticals were worth $238,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in TARS. Quest Partners LLC acquired a new position in Tarsus Pharmaceuticals during the 2nd quarter worth approximately $61,000. Canada Pension Plan Investment Board acquired a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter worth $114,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after purchasing an additional 1,530 shares in the last quarter. Dark Forest Capital Management LP purchased a new position in shares of Tarsus Pharmaceuticals during the second quarter valued at approximately $202,000. Finally, Bleakley Financial Group LLC purchased a new stake in Tarsus Pharmaceuticals in the 1st quarter valued at about $223,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TARS. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Oppenheimer restated an “outperform” rating and set a $63.00 price target (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a research report on Friday, August 9th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $51.60.

Tarsus Pharmaceuticals Trading Down 0.5 %

Tarsus Pharmaceuticals stock opened at $36.45 on Tuesday. Tarsus Pharmaceuticals, Inc. has a 52 week low of $12.84 and a 52 week high of $42.50. The company has a debt-to-equity ratio of 0.28, a quick ratio of 6.99 and a current ratio of 7.03. The firm has a market capitalization of $1.39 billion, a PE ratio of -8.14 and a beta of 1.07. The business’s 50-day simple moving average is $31.17 and its 200-day simple moving average is $31.12.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.10. The company had revenue of $40.81 million during the quarter, compared to analysts’ expectations of $31.30 million. Tarsus Pharmaceuticals had a negative net margin of 180.00% and a negative return on equity of 63.99%. During the same quarter in the prior year, the company posted ($1.17) EPS. Equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.7 earnings per share for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.